Iradimed Selling And Marketing Expenses vs Interest Income Analysis
IRMD Stock | USD 42.03 0.47 1.11% |
Iradimed financial indicator trend analysis is infinitely more than just investigating Iradimed recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Iradimed is a good investment. Please check the relationship between Iradimed Selling And Marketing Expenses and its Interest Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
Selling And Marketing Expenses vs Interest Income
Selling And Marketing Expenses vs Interest Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Iradimed Selling And Marketing Expenses account and Interest Income. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Iradimed's Selling And Marketing Expenses and Interest Income is 0.52. Overlapping area represents the amount of variation of Selling And Marketing Expenses that can explain the historical movement of Interest Income in the same time period over historical financial statements of Iradimed Co, assuming nothing else is changed. The correlation between historical values of Iradimed's Selling And Marketing Expenses and Interest Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling And Marketing Expenses of Iradimed Co are associated (or correlated) with its Interest Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Income has no effect on the direction of Selling And Marketing Expenses i.e., Iradimed's Selling And Marketing Expenses and Interest Income go up and down completely randomly.
Correlation Coefficient | 0.52 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Selling And Marketing Expenses
Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Most indicators from Iradimed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Iradimed current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At present, Iradimed's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 51.10, whereas Selling General Administrative is forecasted to decline to about 9.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 32.0M | 41.3M | 50.2M | 27.1M | Total Revenue | 41.8M | 53.3M | 65.6M | 35.1M |
Iradimed fundamental ratios Correlations
Click cells to compare fundamentals
Iradimed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Iradimed fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 66.7M | 71.1M | 82.9M | 85.5M | 92.2M | 54.5M | |
Other Current Liab | 3.0M | 2.1M | 3.2M | 3.1M | 11.5M | 12.0M | |
Total Current Liabilities | 5.9M | 4.9M | 6.8M | 8.6M | 16.3M | 17.1M | |
Total Stockholder Equity | 55.5M | 61.4M | 72.2M | 73.7M | 71.4M | 46.1M | |
Other Liab | 2.6M | 2.3M | 1.7M | 1.4M | 1.6M | 1.4M | |
Property Plant And Equipment Net | 5.0M | 4.8M | 4.6M | 2.4M | 11.3M | 11.9M | |
Current Deferred Revenue | 1.7M | 1.9M | 2.6M | 3.4M | 2.6M | 1.7M | |
Net Debt | (40.5M) | (47.4M) | (59.5M) | (55.8M) | (47.7M) | (45.3M) | |
Retained Earnings | 36.3M | 37.7M | 47.0M | 47.3M | 43.3M | 27.5M | |
Accounts Payable | 993.7K | 657.1K | 782.9K | 1.8M | 1.9M | 1.0M | |
Cash | 43.5M | 50.1M | 62.0M | 58.0M | 49.8M | 33.0M | |
Non Current Assets Total | 7.8M | 7.3M | 6.6M | 7.3M | 16.2M | 17.0M | |
Non Currrent Assets Other | 232.0K | 262.0K | 201.3K | 2.2M | 4.8M | 5.1M | |
Other Assets | 1.9M | 6.4M | 966.4K | 1.3M | 1.0 | 0.95 | |
Cash And Short Term Investments | 46.3M | 52.0M | 62.5M | 58.0M | 49.8M | 37.0M | |
Net Receivables | 7.3M | 4.6M | 5.1M | 13.3M | 12.2M | 12.8M | |
Common Stock Total Equity | 1.2K | 1.2K | 1.3K | 1.3K | 1.4K | 1.2K | |
Common Stock Shares Outstanding | 12.3M | 12.4M | 12.6M | 12.6M | 12.7M | 13.0M | |
Short Term Investments | 8.1M | 6.3M | 2.8M | 1.9M | 501.9K | 0.0 | |
Liabilities And Stockholders Equity | 66.7M | 71.1M | 82.9M | 85.5M | 92.2M | 54.5M | |
Non Current Liabilities Total | 5.3M | 4.8M | 3.9M | 3.3M | 4.4M | 2.5M | |
Inventory | 3.6M | 3.9M | 4.3M | 5.4M | 12.8M | 13.5M | |
Other Current Assets | 407.8K | 771.7K | 1.0M | 631.0K | 1.2M | 1.3M | |
Other Stockholder Equity | 19.2M | 23.7M | 25.2M | 26.4M | 28.2M | 18.5M | |
Total Liab | 11.2M | 9.7M | 10.7M | 11.8M | 20.7M | 21.8M | |
Property Plant And Equipment Gross | 5.0M | 4.8M | 4.6M | 8.0M | 15.4M | 16.2M | |
Total Current Assets | 59.0M | 63.7M | 76.2M | 78.2M | 76.0M | 49.0M | |
Accumulated Other Comprehensive Income | (42.2K) | 30.4K | 37.1K | 17.0K | 19.6K | 20.5K | |
Short Term Debt | 240.8K | 255.7K | 276.6K | 293.5K | 428.0K | 355.5K | |
Intangible Assets | 860.1K | 960.9K | 1.1M | 2.1M | 2.5M | 2.6M | |
Common Stock | 1.2K | 1.2K | 1.3K | 1.3K | 1.3K | 1.2K | |
Property Plant Equipment | 2.1M | 2.1M | 4.6M | 2.4M | 2.8M | 1.9M | |
Net Tangible Assets | 54.7M | 60.4M | 71.1M | 71.6M | 82.3M | 50.6M | |
Retained Earnings Total Equity | 36.3M | 37.7M | 47.0M | 47.3M | 54.4M | 30.9M | |
Capital Surpluse | 19.2M | 23.7M | 25.2M | 26.4M | 30.4M | 20.7M | |
Net Invested Capital | 55.5M | 61.4M | 72.2M | 73.7M | 71.4M | 64.3M | |
Net Working Capital | 53.1M | 58.8M | 69.4M | 69.6M | 59.7M | 60.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Iradimed Stock analysis
When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Equity Valuation Check real value of public entities based on technical and fundamental data |
Is Iradimed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.185 | Dividend Share 0.15 | Earnings Share 1.4 | Revenue Per Share 5.363 | Quarterly Revenue Growth 0.137 |
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.